Target type: biologicalprocess
Any process that activates or increases the frequency, rate or extent of B cell activation. [GOC:ai]
Positive regulation of B cell activation is a complex process that involves a series of molecular events that ultimately lead to the activation and differentiation of B cells. B cells are a type of white blood cell that plays a crucial role in the adaptive immune response. They are responsible for producing antibodies, which are proteins that bind to specific antigens and target them for destruction.
The activation of B cells is triggered by the binding of antigens to their surface immunoglobulin receptors (BCRs). This binding event initiates a signaling cascade that leads to the activation of various intracellular signaling pathways. These pathways include the MAPK, PI3K, and NF-κB pathways, which regulate gene expression and ultimately lead to the activation of B cells.
One of the key events in B cell activation is the formation of the immune synapse, a specialized structure that forms between the B cell and an antigen-presenting cell (APC). The immune synapse facilitates the delivery of signals from the APC to the B cell, which further promotes B cell activation.
Activated B cells undergo clonal expansion, which involves the rapid proliferation of B cells that express the specific BCR that recognized the antigen. This clonal expansion ensures that a sufficient number of B cells are available to effectively combat the infection.
Activated B cells also differentiate into plasma cells, which are specialized antibody-producing cells. Plasma cells secrete large quantities of antibodies that target the specific antigen that triggered the immune response.
The positive regulation of B cell activation involves a complex interplay of various signaling molecules and transcription factors. These molecules include cytokines, chemokines, and transcription factors that promote the survival, proliferation, and differentiation of B cells.
Overall, positive regulation of B cell activation is a tightly regulated process that ensures that B cells are appropriately activated and differentiated to effectively combat infections.'
"
Protein | Definition | Taxonomy |
---|---|---|
Toll-like receptor 9 | A Toll-like receptor 9 that is encoded in the genome of human. [] | Homo sapiens (human) |
Nucleotide-binding oligomerization domain-containing protein 2 | A nucleotide-binding oligomerization domain-containing protein 2 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q9HC29] | Homo sapiens (human) |
Interleukin-6 | An interleukin-6 that is encoded in the genome of human. [PRO:JAN, UniProtKB:P05231] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
hydroxychloroquine | hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions. Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970) | aminoquinoline; organochlorine compound; primary alcohol; secondary amino compound; tertiary amino compound | anticoronaviral agent; antimalarial; antirheumatic drug; dermatologic drug |
paclitaxel | Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL). | taxane diterpenoid; tetracyclic diterpenoid | antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent |
bergenin | bergenin: RN refers to (2R-(2alpha,3beta,4alpha,4aalpha,10bbeta))-isomer; structure | trihydroxybenzoic acid | metabolite |
docetaxel anhydrous | docetaxel anhydrous : A tetracyclic diterpenoid that is paclitaxel with the N-benzyloxycarbonyl group replaced by N-tert-butoxycarbonyl, and the acetoxy group at position 10 replaced by a hydroxy group. Docetaxel: A semisynthetic analog of PACLITAXEL used in the treatment of locally advanced or metastatic BREAST NEOPLASMS and NON-SMALL CELL LUNG CANCER. | secondary alpha-hydroxy ketone; tetracyclic diterpenoid | antimalarial; antineoplastic agent; photosensitizing agent |
muramyl dipeptide | glycopeptide | immunological adjuvant | |
3-methyl-7-pentyl-8-(2-phenylethylthio)purine-2,6-dione | oxopurine | ||
3-methyl-7-(phenylmethyl)-8-(propan-2-ylthio)purine-2,6-dione | oxopurine | ||
1-(4-methylphenyl)sulfonyl-2-benzimidazolamine | sulfonamide | ||
1-(4-chlorophenyl)sulfonyl-2-benzimidazolamine | sulfonamide | ||
1-(benzenesulfonyl)-2-benzimidazolamine | sulfonamide | ||
1-(4-nitrophenyl)sulfonyl-2-benzimidazolamine | sulfonamide | ||
pd 166285 | |||
1-(4-methoxyphenyl)sulfonyl-2-benzimidazolamine | sulfonamide | ||
5,6-dimethyl-1-(4-methylphenyl)sulfonyl-2-benzimidazolamine | sulfonamide | ||
bi 653048 bs h3po4 | BI 653048 BS H3PO4: structure in first source |